Skip to main content

Table 4 A prognostic signature for patients with ER- breast cancer

From: Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value

ER negative dataset (sample size) Clinical end points Log-rank test Univariate HR   Multivariate HR
   P value HR (95% CI low-high) P value HR (95% CI low-high) P value
BR1141(40) RFS 0.828 1.1(0.4-3.0) 0.828 NA# NA
BR2411(69) RFS 0.590 1.3(0.5-2.9) 0.591 NA NA
BRGSE20624(115) RFS 0.442 1.3(0.5-3.0) 0.602 NA NA
BR25055(131) DRFS 0.406 1.3(0.7-2.5) 0.406 NA NA
BR1405(77) RFS 0.015 2.5(1.2-5.4) 0.015 NA NA
BRGSE21653(113) DFS 0.022 2.1(1.1-3.9) 0.022 2.5(1.1-5.4) 0.023
BRMetabric DSS 0.001 2.2(1.4-3.7) 0.001 2.4(1.1-5.2) 0.022
D22522925(196)
BRMetabric DSS 0.015 1.6(1.1 -2.5) 0.015 1.7(1.0-2.9) 0.036
V22522925(244)
BRTCGA(118) OS 0.003 13.8(1.4-34.6) 0.003 3.2(1.5-5.2) 0.025
  1. Note: Multivariate HR adjusted factors in each test dataset are as follows: BRGSE21653 (grade, PR, HER2 status, ki67), BRMetabricD22522925 and BRMetabricV22522925 (age, menopausal status, grade, size, stage, lymph node positivity, NPI, HER2 status, PAM50 subtype, treatment), BRTCGA (PR, HER2 status, T stage).
  2. #: No adjusted clinical covariates; no mulitvariate HR analysis was performed.